Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer.
Kyung-Min LeeHyebin LeeDohyun HanWoo Kyung MoonKwangsoo KimHyeon Jeong OhJinwoo ChoiEun Hye HwangSeong Eun KangSeock-Ah ImKyung-Hun LeeHan-Suk RyuPublished in: Breast cancer research : BCR (2020)
Our results indicate that, before chemotherapy, an initial screening of YARS protein expression should be performed, and YARS-positive breast cancer patients might consider the combined treatment with LCL161 and ABT-263; this could be a novel stepwise clinical approach to apply new targeted therapy in breast cancer patients in the future.